查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
新城疫疫苗全球市场-2022-2029
市场调查报告书
商品编码
1140685

新城疫疫苗全球市场-2022-2029

Global Newcastle Disease Vaccine Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

市场进入者对新疫苗的研发不断增加，正在推动市场的增长。

推动市场增长的主要因素之一是动物公司推出的新动物疫苗的数量。此外，未来越来越多的管道产品进入将进一步促进市场的增长。例如，2022 年 5 月，基于新城疫病毒的三价疫苗对小鼠的 SARS-CoV-2 变体有效。本研究的结果表明，其三价製剂由祖先的武汉、Delta 和 Beta NDV-HXP-S 变体组成，对包括 Omicron 在内的系统发育较远的 SARS-CoV-2 变体具有更高水平的抗病毒活性。被证明可以诱导交叉中和抗体。

此外，预测期内新兴国家的增长也将推动市场的增长。由于对肉类的需求不断增长，中国已成为畜牧业动物保健产品的最大市场之一。中国国家统计局数据显示，2021年中国猪肉产量同比增长28.8%。 2021年中国肉类总产量为5296万吨。此外，影响牲畜的疾病对动物生产力和肉类等食品具有破坏性影响。该倡议旨在通过提供预防这些疾病的途径，减少非洲小农户因新城疫、体内寄生虫、东海岸热和口蹄疫而遭受的年度损失。

地理渗透。

北美将是预测期内的主要地区。

在预测期内，北美市场以最大的市场份额引领全球新城疫疫苗市场。家禽相关食品消费量的增加、禽类疾病的高发病率、消费者对食品安全的看法等是推动该地区市场增长的因素，尤其是在美国。此外，家禽生产的繁荣对该地区的市场主导地位起着重要作用。根据联合国粮食及农业组织（UNFAO）的数据，美国是世界上最大的鸡肉生产国，2020年美国的鸡总数为5.183亿隻。此外，该国正在通过联合战略项目和收购推进家禽疫苗的引进，以进一步促进更好的家禽健康。

此外，预计亚太地区将在预测期内达到全球最高的复合年增长率。对家禽疫苗的认识不断提高，加上该地区疫苗接种宣传活动的增加，是预计在预测期内为市场提供增长机会的一些因素。

竞争格局。

新城疫疫苗市场由少数公司主导。市场增长的主要参与者包括 Boehringer Ingelheim、Seba Animal Health LLC、CAVAC、GALVmed、Hester Biosciences Limited、Merck Animal Health、Elanco、Zoetis, Inc 和 QYH Biotech。主要参与者将执行多项增长战略，例如产品发布、收购和合作，据估计这些战略将促进全球新城疫疫苗市场的增长。几家主要的主要参与者已经在市场上推出了新的疫苗，以保护动物免受各种疾病的侵害。例如，2020年1月，勃林格殷格翰推出了一种名为VAXXITEK HVT+IBD+ND的疫苗，用于保护家禽免受马立克氏病、传染性法氏囊病（经典和变异）、新城疫等疾病的影响。该公司在其位于佐治亚州的生产基地生产这种疫苗，该基地每年生产超过 600 亿剂家禽疫苗，供包括美国在内的 60 多个国家使用。 2022 年 6 月，Sebasante 收购了加拿大公司 Artemis Technologies, Inc.，以扩大其口服狂犬病疫苗产品组合。通过此次收购，Ceva 扩大了其在北美的业务。 2020 年 4 月，印度古瓦哈蒂理工学院和 Hester Biosciences 联合开发了一种新的冠状病毒疫苗（COVID-19）。该疫苗基于重组禽副粘病毒载体平台。

COVID-19 的影响将对全球新城疫疫苗市场产生负面影响。

COVID-19 的爆发无疑影响了全球新城疫疫苗市场。封锁迫使兽医关闭了他们的业务，即使在兽医开放的情况下，公众也害怕在他们开放的时候去他们那里接种疫苗。因此，新城疫疫苗市场在 2020 年显着下降。在 COVID-19 大流行之后，为防止疾病传播而对动物疫苗接种的严格规定预计将在未来几年推动市场增长。

内容

第 1 章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按类型划分的市场细分
  • 按应用划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
  • 促进因素
    • 全球肉类消费量增加
    • 新城疫疫苗新兴市场
  • 抑制因素
    • 与疫苗相关的高成本
  • 机会
  • 影响分析

第 5 章行业分析

  • 波特五力分析
  • 供应链分析
  • 价值链分析
  • PEST 分析
  • 定价分析
  • 监管分析
  • 保险报销分析
  • 未满足的需求
  • 专利趋势

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按类型

  • 活疫苗
  • 灭活□□疫苗
  • 耐热疫苗

第 8 章按应用程序

  • 鸡
  • 火鸡
  • 其他

第 9 章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 10 章竞争格局

  • 竞争场景
  • 市场定位/市场份额分析
  • 併购分析

第 11 章公司简介

  • Boehringer Ingelheim
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Ceva Animal Health LLC
  • CAVAC
  • GALVmed
  • Hester Biosciences Limited
  • Merck Animal Health
  • Elanco
  • QYH Biotech
  • Zoetis, Inc.
  • Merial
  • ChengDu Tecbond
  • Ringpu Biology
  • Qingdao Yebio Bioengineering Co. Ltd.
  • Other Companies

第 12 章 DataM

简介目录
Product Code: DMHCIT3001

Market Overview

Newcastle Disease Vaccine Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 3.6 % during the forecast period (2022-2029).

Newcastle disease is a contagious disease of birds that affects many avian species, both wild and domestic animals, and it is transmissible to humans. Several Newcastle disease vaccines available in the global market are appropriate for commercial chickens. The I-2 Newcastle disease vaccine, a thermostable vaccine, has been manufactured for local or regional development and tackles Newcastle disease in village chickens. After storage for 1-2 hours at room temperature, numerous Newcastle disease vaccinations deteriorate. It renders them unsuitable for use in villages where the vaccine must be transferred at room temperature for hours or days. Raising vaccines to limit outbreaks of avian disease and the increasing demand for food items related to poultry drive the global market's growth. The growing awareness drives the market among veterinary practitioners of animal vaccination, rising government food safety initiatives, and increasing meat consumption.

Market Dynamics: Rising R&D for the new vaccine by market players leads the market's growth.

One of the major factors augmenting the market's growth includes the number of new veterinary vaccines introduced by animal companies. Besides, increasing pipeline products that will enter the future further contribute to market growth. For instance, in May 2022, the Newcastle disease virus-based trivalent vaccine was effective across SARS-CoV-2 variants in mice. The present study findings demonstrated that its trivalent formulation, composed of the ancestral Wuhan, Delta, and Beta NDV-HXP-S variants, induced substantially high levels of cross-neutralizing antibodies against the phylogenetically distant SARS-CoV-2 variants, including Omicron.

Also, growth in emerging economies during the forecast period drives market growth. China's increasing demand for meat makes it one of the largest markets for animal healthcare products for livestock animals. According to the National Bureau of Statistics of China, pork production in China was up 28.8% year-on-year in 2021. China's total meat production is 52.96 million tons in the year 2021. Moreover, the diseases that affect livestock pose a devastating impact on animals' productivity and food products such as meat and other animal products. The initiative aims to reduce smallholder farmers' annual losses in Africa from Newcastle disease of poultry and endoparasites and East Coast fever and Foot-and-mouth disease by providing access to prevent such diseases.

Market Segmentation: Thermostable vaccine segment accounted for the highest share in global newcastle disease vaccine market.

The thermostable vaccine is expected to project the highest CAGR in the Newcastle disease vaccine market during the forecast period. This significant growth is due to its resistance to inactivation on exposure to high temperatures. Thermostable Newcastle disease virus (NDV) vaccines are used extensively to protect village chickens against Newcastle disease, backed by their decreased dependence on the cold chain for transport and storage. Though, the genetic basis underlying NDV thermostability is poorly understood.

By application, the newcastle disease vaccine market is classified into chicken, turkey, and others. A chicken segment held a significant role in the global Newcastle disease vaccine market during the forecast period. Chickens are susceptible to various infectious diseases. The viral disease known as Newcastle disease causes catastrophic losses to both village and commercial chickens and is among the most significant diseases that occur to chickens. Reducing large numbers of village chickens to Newcastle's contagious disease is a major first step in enhancing their productivity, driving the need for Newcastle disease vaccine chickens.

Geographical Penetration: North America is the dominating region during the forecast period.

The North American market leads with the largest market share in the global Newcastle disease vaccine market during the forecast period. Increased consumption of poultry-related food items, a high incidence of avian diseases, and consumer perception of food safety are some factors driving the market growth in the region, especially in the U.S. Moreover, poultry meat's thriving production has played a crucial role in the region's dominance in the market. According to the United Nations Food and Agriculture Organization (UNFAO), the U.S. is the largest producer of poultry meat globally; accounting For 2020, the number of all chickens in the United States totaled around 518.3 million. Furthermore, the country's adoption of poultry vaccines is being driven by joint strategic projects and acquisitions to foster better avian health further.

Moreover, the Asia Pacific region is expected to project the highest CAGR globally during the forecast period. The growing awareness of poultry vaccines coupled with the increase in the number of vaccination awareness programs in the region is some factors that are expected to offer growth opportunities to the market during the forecast period.

Competitive Landscape:

The Newcastle disease vaccine market is dominated by a few companies. Some of the key players in the market's growth include Boehringer Ingelheim, Ceva Animal Health LLC, CAVAC, GALVmed, Hester Biosciences Limited, Merck Animal Health, Elanco, Zoetis, Inc., and QYH Biotech, among others. The key players execute several growth strategies, such as product launches, acquisitions, and collaborations, which are estimated to boost the Newcastle disease vaccine market growth globally. Some major key players launched new vaccines in the market to protect animals from various diseases. For instance, in January 2020, Boehringer Ingelheim launched a vaccine named VAXXITEK HVT+IBD+ND to protect poultry from the diseases like Marek's Disease, Infectious Bursal Disease (classic and variant types) and Newcastle Disease. The Company manufactured this vaccine at its manufacturing site in Georgia, which produced more than 60 billion doses of poultry vaccine a year for use in the United States and over 60 other countries. In June 2022, Ceva Sante acquired Canadian Firm Artemis Technologies, Inc. to expand its oral rabies vaccine portfolio. Through this acquisition, Ceva expands its presence in North America. In April 2020, the Indian Institute of Technology Guwahati and Hester Biosciences collaborated to develop a new vaccine against coronavirus (COVID-19). This vaccine is based on a recombinant avian paramyxovirus vector platform.

COVID-19 Impact: Negative impact on the global newcastle disease vaccine market.

The outbreak of COVID-19 has certainly impacted the global Newcastle disease vaccine market. The lockdown has compelled the veterinaries to close their operations, or even if the vets are open, the public was afraid to visit vets for vaccination in the meantime. Therefore, the Newcastle disease vaccine market significantly declined in 2020. Stringent regulations after the COVID-19 pandemic regarding the vaccinations of animals to prevent disease spread are expected to propel market growth in the next couple of years.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. The rise in consumption of meat globally
    • 4.2.2. Emerging markets of Newcastle Disease Vaccine
  • 4.3. Restraints:
    • 4.3.1. High cost associated with vaccines.
  • 4.4. Opportunity
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
  • 7.3. Market Attractiveness Index, By Type Segment
    • 7.3.1. Live Vaccines
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Killed Vaccines
    • 7.3.3. Thermostable Vaccines

8. By Application

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 8.3. Market Attractiveness Index, By Application Segment
    • 8.3.1. Chicken
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Turkey
    • 8.3.3. Others

9. By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. The U.S.
      • 9.4.5.2. Canada
      • 9.4.5.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. Germany
      • 9.5.5.2. The U.K.
      • 9.5.5.3. France
      • 9.5.5.4. Italy
      • 9.5.5.5. Spain
      • 9.5.5.6. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.5.1. Brazil
      • 9.6.5.2. Argentina
      • 9.6.5.3. Rest of South America
  • 9.7. Asia Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.5.1. China
      • 9.7.5.2. India
      • 9.7.5.3. Japan
      • 9.7.5.4. Australia
      • 9.7.5.5. Rest of Asia Pacific
  • 9.8. The Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Boehringer Ingelheim*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Ceva Animal Health LLC
  • 11.3. CAVAC
  • 11.4. GALVmed
  • 11.5. Hester Biosciences Limited
  • 11.6. Merck Animal Health
  • 11.7. Elanco
  • 11.8. QYH Biotech
  • 11.9. Zoetis, Inc.
  • 11.10. Merial
  • 11.11. ChengDu Tecbond
  • 11.12. Ringpu Biology
  • 11.13. Qingdao Yebio Bioengineering Co. Ltd.
  • 11.14. Other Companies

12. DataM Intelligence

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us